StageZero Life Sciences Ltd.
SZLSF
$0.0021
-$0.025-92.25%
| Weiss Ratings | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.37 | |||
| Price History | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -89.50% | |||
| 30-Day Total Return | 23.53% | |||
| 60-Day Total Return | 31.25% | |||
| 90-Day Total Return | -97.36% | |||
| Year to Date Total Return | 31.25% | |||
| 1-Year Total Return | -93.33% | |||
| 2-Year Total Return | -97.36% | |||
| 3-Year Total Return | -98.61% | |||
| 5-Year Total Return | -99.13% | |||
| 52-Week High % Change | -99.79% | |||
| 52-Week Low % Change | 40.00% | |||
| Price | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 12, 2024 | |||
| 52-Week High Price (Date) | Aug 30, 2024 | |||
| Valuation | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.42M | |||
| Enterprise Value | 5.41M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -90.33% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.18 | |||
| Price/Book (Q) | -0.02 | |||
| Enterprise Value/Revenue (TTM) | 3.84 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -4.29 | |||
| Enterprise Value/EBIT | -4.04 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 123.53M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 70 East Beaver Creek Road Richmond Hill, ON L4B 3B2 | |||
| Website | www.stagezerolifesciences.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -- | |||
| Net Income Avl. to Common (TTM) | -- | |||
| Total Revenue Growth (Q YOY) | -32.97% | |||
| Earnings Growth (Q YOY) | 51.42% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | 60.49% | |||
| Balance Sheet | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 15.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 235.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -11.13M | |||
| Current Ratio (Q) | 0.023 | |||
| Book Value Per Share (Q) | -$0.09 | |||
| Total Assets (Q) | 580.70K | |||
| Total Current Liabilities (Q) | 10.33M | |||
| Total Debt (Q) | 2.13M | |||
| Total Liabilities (Q) | 11.71M | |||
| Total Common Equity (Q) | -11.13M | |||
| Cash Flow | SZLSF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
